MG98, a Second-Generation DNMT1 Inhibitor, in the Treatment of Advanced Renal Cell Carcinoma

Abstract

Background: In carcinogenesis, methylation of DNA promoter regions results in inactivation of tumor-suppressing genes. MG98 was designed to inhibit DNA methyltransferases enzyme 1 production.

Methods: This multicenter study explored two schedules of MG98 with Interferon-α-2β to identify schedule and dose for patients with metastatic RCC.

Results: Doses of IFN 9 MIU/MG98 125 mg/m² for a continuous schedule and IFN 9 MIU/MG98 200 mg/m² for an intermittent schedule were considered the MTDs. Treatment resulted in one PR and eight SD.

Conclusion: MG98 combined with IFN was safe and resulted in clinical activity.

Keywords: :

• Kidney cancer
• Tumor suppressor gene
• DNA methylation
• CpG
• DNMT
• Interferon
• MG98